SEC Tracker
Get the app
SABS · XBRL financial data

SAB Biotherapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (SABS's year ends in late December)

In thousands of dollarsDec 31, 2023†Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Revenue from contracts with customers305*9452630*115*———year only———
Research and development4,297*8,1466,8227,8317,652*7,6576,9978,97010,728*13,39816,17218,077
General and administrative14,881*4,1893,6433,4792,472*3,1152,7353,7095,042*6,6007,2057,822
Total operating expenses19,179*12,33510,46511,30910,124*10,7729,73212,67915,770*19,99823,37725,899
Operating income (loss)(18,874)*(11,391)(10,202)(11,309)(10,009)*(10,772)(9,732)(12,679)(15,770)*(19,998)(23,377)(25,899)
Interest expense78*76937871*70644363*6362—
Income tax expense (benefit)year only———year only———year only———
Net income (loss)(22,857)*(5,026)(7,335)(10,349)(11,395)*(5,197)(10,114)45,445(16,861)*(18,869)(22,491)(22,300)
Earnings per share, basic USD per share—(0.54)(0.79)(1.12)(1.23)*(0.56)(1.09)0.50—(0.35)(0.28)(0.24)
Earnings per share, diluted USD per share—(0.54)(0.79)(1.12)(1.23)*(0.56)(1.09)(0.21)—(0.35)(0.28)(0.24)
Weighted average shares, basic thousands of shares—9,2429,2559,2599,291*9,2929,29410,661—53,55979,75393,238
Weighted average shares, diluted thousands of shares—9,2429,2559,2599,291*9,2929,29477,863—53,55979,75393,238
  • † Share count changed about 10x in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (SABS's year ends in late December)

In thousands of dollarsDec 31, 2023†Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents56,56614,03417,2429,1718,8985,6403,69229,42510,50320,5208,26714,438
Short-term investments030,02320,08421,22911,8637,2102,02181,45686,09086,87294,36589,611
Accounts receivable0———————————
Prepaid and other current assets2,3412,7012,0302,0392,9773,4253,5951,8363,5133,8353,4612,185
Total current assets58,90746,95139,58032,53723,79216,2979,308113,277101,053112,782107,937107,738
Property and equipment, net19,73717,90316,92116,07715,36814,61113,85813,11413,30613,81414,22915,652
Right-of-use asset1,2781,0801,2421,0659703,2023,0062,8072,6032,8851,9011,723
Total assets83,94171,37161,89253,79744,19538,12030,129183,448172,810248,470238,210235,644
Accounts payable9461,2401,1711,2971,6952,5202,6222,9553,1463,5453,8552,423
Total current liabilities10,8138,3057,5528,8167,9809,65310,67710,79310,6819,85211,70514,798
Lease liability, non-current6365557826835812,4672,2552,0371,8772,1711,4511,350
Total liabilities26,64218,54915,77216,89518,22616,71318,11318,37421,31621,22223,42524,723
Accumulated deficit(90,064)(95,089)(102,425)(112,774)(124,169)(129,366)(139,480)(94,034)(110,895)(129,764)(152,255)(174,555)
Total stockholders' equity57,29952,82246,12036,90325,97021,40712,016165,074151,494227,248214,785210,921
Total liabilities and equity83,94171,37161,89253,79744,19538,12030,129183,448172,810248,470238,210235,644
Common shares outstanding (cover page)‡ thousands of shares9239,2299,2299,2299,2899,29210,41147,60750,95176,46490,98690,089
  • ‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (January 2024); filings made before it reported them unadjusted.
  • † Share count changed about 10x in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (SABS's year ends in late December)

In thousands of dollarsDec 31, 2023†Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)(22,857)*(5,026)(7,335)(10,349)(11,395)*(5,197)(10,114)45,445(16,861)*(18,869)(22,491)(22,300)
Stock-based compensation537*617601*1,049*674*613627*801*3,170*5,4607,247*7,437*
Depreciation and amortization922*1,9631,000900764*757800700742*731800800
Net cash from operating activities(13,447)*(10,750)(7,718)*(6,292)*(9,532)*(7,797)(7,152)*(13,050)*(16,776)*(14,271)(9,841)*(13,023)*
Purchases of property and equipment68*12953*100*55*———year only9831,586*1,343*
Net cash from investing activities(68)*(31,359)11,219*(1,153)*9,331*4,6715,198*(129,869)*(1,706)*(65,648)(4,883)*6,069*
Net cash from financing activities67,637*(394)(321)*(674)*217*(174)(174)*168,689*(42)*89,9212,364*13,001*
Net change in cash54,141*(42,532)3,208*(8,071)*(273)*(3,258)(1,948)*25,732*(18,922)*10,017(12,253)*6,171*
  • † Share count changed about 10x in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
SAB Biotherapeutics14,438not reported(13,023)*90.1M7.6 quarters 10-QSep 30, 2026
XBiotech109,528not reported(4,515)*30.5M24.3 quarters 10-QJun 30, 2026
Oramed Pharmaceuticals15,245not reported(200)*41.6M189.8 quarters 10-QJun 30, 2026
Inovio Pharmaceuticals31,5260(18,047)*103.4M2.0 quarters 10-QJun 30, 2026
Macrogenics113,90732,832(40,748)*63.7M2.8 quarters 10-QJun 30, 2026
Volitionrx2,800399(5,160)*13.6M0.5 quarters 10-QJun 30, 2026
Gyre Therapeutics43,28729,105(16,728)*111.5M3.4 quarters 10-QJun 30, 2026
Oncolytics Biotech4,115not reported(8,138)*127.5M0.5 quarters 10-QJun 30, 2026
Elicio Therapeutics30,900not reported(10,364)*28.3M3.1 quarters 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.